Market Place
Sourcing Support
World Stroke Congress: TASTE-2 Reduces Stroke Disability
30 Oct 2024 //
PR NEWSWIRE
Sanbexin® Significantly Reduces Stroke Disability at TASTE-2
25 Oct 2024 //
PR NEWSWIRE
Sanbexin Sublingual Tablets Granted Breakthrough Therapy Status By FDA
14 Sep 2024 //
PR NEWSWIRE
Connect Biopharma Reports First Half 2024 Financial Results
05 Sep 2024 //
GLOBENEWSWIRE
Sanbexin Sublingual Tablets Receive FDA Breakthrough Therapy Designation
05 Sep 2024 //
PR NEWSWIRE
Simcere Zaiming, TargetRx Enter Collaboration Agreement Focused on TGRX-326
03 Sep 2024 //
CONTRACT PHARMA
Simcere Zaiming Partners With TargetRx On Third-Generation ALK Inhibitor
02 Sep 2024 //
PR NEWSWIRE
Simcere and Connect Enter into license and collaboration agreement
23 Nov 2023 //
PR NEWSWIRE
California biotech Connects with Simcere in $141M licensing pact
21 Nov 2023 //
FIERCE BIOTECH
Simcere Announces Agreement with Boston-based Mass General Brigham
12 Jun 2023 //
BUSINESSWIRE
Simcere is on the Fast Track Toward Building an Global Pharmaceutical Company
24 Apr 2023 //
PR NEWSWIRE
Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235
14 Mar 2023 //
PR NEWSWIRE
First Prescription for COSELA® (trilaciclib) Issued in China
09 Feb 2023 //
PR NEWSWIRE
China approves two domestically developed COVID drugs
29 Jan 2023 //
REUTERS
Ascletis Announces Entering into a Agreement of Ritonavir Tablets with Simcere
16 Jan 2023 //
PR NEWSWIRE
PHASE II/III CLINICAL TRIAL OF SIMCERE`S 3CL-TARGETING ANTI-SARS-COV-2 DRUG
20 Dec 2022 //
PR NEWSWIRE
For $30M, Simcere picks up regional rights to Idorsia’s insomnia drug
16 Nov 2022 //
ENDPTS
Idorsia and Simcere enter into a licensing agreement for daridorexant in China
16 Nov 2022 //
GLOBENEWSWIRE
Simcere and Idorsia enter into a licensing agreement for daridorexant in China
15 Nov 2022 //
PRNEWSWIRE
Simcere Receives FDA Clearance of IND for Bi-functional Fusion Protein, SIM0237
27 Oct 2022 //
PRNEWSWIRE
Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc
30 Sep 2022 //
PRESS RELEASE
Simcere Pharmaceutical Announces Financial Results for 2022 H1
05 Sep 2022 //
PRNEWSWIRE
Tamas Oravecz named SVP, CSO of the U.S. of Simcere Pharmaceutical Group
05 Sep 2022 //
PRNEWSWIRE
SIMCERE PHARMA`s 3CLpro SIM0417 Received Second Clinical Trial Approval in China
17 May 2022 //
PRNEWSWIRE
Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials
18 Apr 2022 //
PRNEWSWIRE
Primary endpoint met in Phase III trial of Trilaciclib in Chinese patients
24 Feb 2022 //
PRNEWSWIRE
Simcere Pharma (2096.HK) Announces a Positive Profit Alert
22 Feb 2022 //
PRNEWSWIRE
Bijoyesh Mookerjee Appoints CMO, Oncology for Simcere Pharmaceuticals
07 Feb 2022 //
PRNEWSWIRE
Aeromics, Simcere Begins First-In-Human Dosing in Phase I of SIM0307 (AER-271)
09 Dec 2021 //
PRNEWSWIRE
Simcere, SIMM Collaborate for Next-Gen COVID-19 Oral Antivirals
22 Nov 2021 //
PRNEWSWIRE
Alzheimer`s gold rush inspires $565M deal between Chinese pharma powerhouse
29 Jun 2021 //
ENDPTS
